MAPK1 and fragile X syndrome: Furthermore, we predicted acamprosate treatment would decrease pERK/ERK total ratios based on data showing drugs with similar anti-glutamatergic actions to acamprosate significantly decreased aberrant ERK1/2 activation in Fmr1 KO mice and decreased ERK1/2 activation kinetics in FXS patient blood samples [7, 75].